Volume 126, Issue 5 pp. E191-E195
Head and Neck

Reduced serum levels of syndecan-1 in patients with tongue squamous cell carcinoma

Mohammad Sohrabi Shegefti MD

Mohammad Sohrabi Shegefti MD

Department of Immunology , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Search for more papers by this author
Mahyar Malekzadeh MSc

Mahyar Malekzadeh MSc

Institute for Cancer Research , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Search for more papers by this author
Zahra Malek-Hosseini MSc

Zahra Malek-Hosseini MSc

Department of Immunology , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Search for more papers by this author
Bijan Khademi MD

Bijan Khademi MD

Department of Otolaryngology , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Search for more papers by this author
Abbas Ghaderi PhD

Abbas Ghaderi PhD

Department of Immunology , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Institute for Cancer Research , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Search for more papers by this author
Mehrnoosh Doroudchi PhD

Corresponding Author

Mehrnoosh Doroudchi PhD

Department of Immunology , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Institute for Cancer Research , School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Send correspondence to Dr. Mehrnoosh Doroudchi, Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, P.O. Box: 71345-3119, Postal Code: 71348-45794, Shiraz, Iran. E-mail: [email protected]Search for more papers by this author
First published: 15 December 2015
Citations: 6

This work was performed as part of Mohammad S. Shegefti's dissertation as a requirement for graduation as a General Practitioner from Shiraz School of Medicine, Shiraz, Iran.

This work was financially supported by a grant (90-01-01-2815) from Shiraz University of Medical Sciences and from the Shiraz Institute for Cancer Research (ICR-100-502), Shiraz, Iran.

The authors have no funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

To investigate soluble syndecan-1 (Sdc-1) in the sera of patients with tongue squamous cell carcinoma (SCC) and its correlation with the histopathological criteria of tumors.

Study Design

In a case-control study using a convenient method of sampling, 18 female and 25 male patients with confirmed diagnosis of tongue SCC, and 19 healthy females and 27 males were studied.

Methods

Soluble Sdc-1 was measured in the sera of 43 patients with tongue SCC and was compared with that of healthy age-/sex-matched controls using a commercial enzyme-linked immunosorbent assay. Clinical and pathological data, along with the demographic characteristics of the patients, were recorded at the time of sampling.

Results

The levels of soluble Sdc-1 were decreased in the sera of patients compared to controls (91.17 ± 88.60 vs. 158.17 ± 103.47 ng/mL, P = .002). Although patients who smoke tended to have higher grades (P = .043), there was no significant difference in the level of syndecan-1 between smokers and non-smokers. A significant difference between syndecan-1 in the sera of patients with tumors of different stages was observed (Kruskal-Wallis test P=0.039); however, scarcity of patients in stages I and III decreased the power of the comparison.

Conclusions

Sdc-1 levels in the sera of patients do not correlate with the tumor progression in the tongue SCC. This is in contrast with the reported inverse correlation between the expression level of membranous Sdc-1 and the histological grade and size of head and neck tumors. Therefore, Sdc-1 shedding may not be a major mechanism in the progressive loss of its expression regarding tongue tumor.

Level of Evidence

NA Laryngoscope, 126:E191–E195, 2016

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.